Pfizer Inc. (NYSE:PFE) Shares Sold by Kathleen S. Wright Associates Inc.

Kathleen S. Wright Associates Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 6.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 11,225 shares of the biopharmaceutical company’s stock after selling 775 shares during the period. Kathleen S. Wright Associates Inc.’s holdings in Pfizer were worth $296,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Commonwealth Financial Services LLC lifted its stake in shares of Pfizer by 139.5% in the fourth quarter. Commonwealth Financial Services LLC now owns 35,063 shares of the biopharmaceutical company’s stock valued at $930,000 after purchasing an additional 20,421 shares during the period. Tempus Wealth Planning LLC increased its holdings in Pfizer by 35.3% in the fourth quarter. Tempus Wealth Planning LLC now owns 24,768 shares of the biopharmaceutical company’s stock valued at $657,000 after buying an additional 6,467 shares in the last quarter. Flavin Financial Services Inc. acquired a new stake in shares of Pfizer during the 4th quarter valued at approximately $748,000. Calamos Wealth Management LLC boosted its stake in shares of Pfizer by 0.9% during the 4th quarter. Calamos Wealth Management LLC now owns 52,474 shares of the biopharmaceutical company’s stock worth $1,392,000 after acquiring an additional 469 shares in the last quarter. Finally, Calamos Advisors LLC grew its holdings in shares of Pfizer by 70.2% in the 4th quarter. Calamos Advisors LLC now owns 1,642,574 shares of the biopharmaceutical company’s stock worth $43,577,000 after acquiring an additional 677,341 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on PFE. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Citigroup decreased their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Sanford C. Bernstein started coverage on Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Price Performance

Shares of Pfizer stock opened at $26.23 on Tuesday. The stock has a market capitalization of $148.62 billion, a P/E ratio of 35.44, a PEG ratio of 0.66 and a beta of 0.64. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The business’s fifty day moving average price is $26.27 and its 200 day moving average price is $27.85. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. As a group, research analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.56%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is currently 232.44%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.